{"id":924979,"date":"2026-07-10T07:08:48","date_gmt":"2026-07-10T07:08:48","guid":{"rendered":"https:\/\/www.europesays.com\/us\/924979\/"},"modified":"2026-07-10T07:08:48","modified_gmt":"2026-07-10T07:08:48","slug":"glp-1-trials-reveal-diet-quality-gap-as-companion-products-boom","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/924979\/","title":{"rendered":"GLP-1 trials reveal diet quality gap as companion products boom"},"content":{"rendered":"

Many GLP-1 clinical trials are not tracking what patients are consuming, pointing to a gap in the weight-loss market. Nutrition Insight asks FrieslandCampina Ingredients<\/a>, Probi, Roquette, and HTBA what this data gap means for nutrition industry innovators developing solutions for GLP-1 users today.\u00a0<\/p>\n

A scoping review in Advances in Nutrition<\/a> from last year of 129 randomized trials investigated liraglutide, semaglutide, or tirzepatide in humans. Only 57 trials included lifestyle modification activities, and only 36 recorded diet quality and food intake. Of this, only 10 trials reported outcomes, while only 17 trials assessed food cravings or eating behavior.<\/p>\n

Despite the mainstream appeal of GLP-1 agonist drugs, researchers flag that most trials lacked detailed reporting on nutritional behaviors.<\/p>\n

\"arrow\"<\/a>From gap to opportunity<\/p>\n

There are real implications for how companion products are being developed since the industry is working with an insufficient picture of consumers\u2019 eating behaviors, notes Penny Antonopoulos, marketing manager for Performance and Active Nutrition at FrieslandCampina Ingredients.<\/p>\n

\u201cThe clinical evidence base for GLP-1 medications is strong on weight loss outcomes, but notably light on dietary data in key areas such as what users are actually eating and how their nutritional status shifts over time.\u201d\u00a0<\/p>\n

\u201cThis highlights an opportunity for the industry: designing solutions around how people actually eat when using GLP\u20111 medications. Products that are too large, too heavy, or require too much effort simply don\u2019t endure in this context. Success will depend on creating nutrient-dense solutions that are easy to consume, support digestive comfort, and fit naturally into low-appetite moments.\u201d<\/p>\n

\u201cFeeding the microbiome\u201d<\/p>\n

Based on the lack of detailed dietary tracking in GLP\u20111 trials, Brandy Webb, ND, scientific affairs manager at Probi USA, infers that it leaves the nutrition industry navigating an \u201cincomplete map.\u201d<\/p>\n

\u201cWe don\u2019t yet have strong evidence on how specific nutrients or food patterns interact with these drugs, so, while many current products are built on well-reasoned hypotheses, they are not substantiated by trial-driven dietary data.\u201d<\/p>\n

\u201cFrom a microbiome lens, this gap matters. GLP\u20111s reduce appetite and slow gastric emptying, which often leads to lower fiber and micronutrient intake \u2014 key inputs for a healthy gut. Over time, that can lead to nutrient deficiencies as well as shrink microbial diversity and reduce production of beneficial short-chain fatty acids (SCFAs).\u201d<\/p>\n

Furthermore, she explains that such consequences can be opportunities for precision nutrition solutions and targeted biotic solutions to \u201cfeed the microbiome\u201d even when overall consumption drops.<\/p>\n

\"Close-upOnly 17 of 129 GLP-1 trials assessed food cravings or eating behavior in participants.\u201cIn the first case, products must supply nutrients relevant to GLP-1 users, such as fiber, protein, and certain micronutrients, using formats that are easy to digest. In the latter case, the most promising approaches will focus on bacterial strains, including specific probiotic strains, and substrates that support SCFA production, gut barrier function, and gut-brain signaling.\u201d<\/p>\n

Respond to what is known<\/p>\n

Elodie Dehay Harmel, Nutrition & Health research scientist at Roquette, reflects on clinical trials with GLP-1 receptor agonists, pointing out that they have mainly focused on showing effects on certain physiological outcomes such as glycemic control, appetite regulation, and weight loss.<\/p>\n

\u201cWhile overall caloric intake is typically assessed, detailed tracking of dietary composition is rarely included, leaving a gap in our understanding of what consumers actually eat. However, while scientists may not always track what GLP-1 analog users are eating, those taking the medications often do, providing useful real-world insights.\u201d\u00a0<\/p>\n

\u201cEven for those who don\u2019t, there are certainly actions that the industry can, and should, take to support this growing consumer group,\u201d she stresses. \u201cWe know that GLP-1 medications can reduce appetite, so developing smaller, nutrient-dense portions is a smart response to changing eating habits.\u201d<\/p>\n

Concurrently, GLP-1 analog users are also encouraged to have more active lifestyles during treatment, which means convenience on-the-go becomes important to consider, Dehay Harmel notes.<\/p>\n

\u201cConsumers also want to quickly understand how a product supports their goals. Brands should clearly communicate the nutritional role of a food or supplement, whether that\u2019s providing protein to support satiety and muscle health, fiber to support digestive wellness, or other key nutrients \u2014 such as energy.\u201d<\/p>\n

\"MatureGLP-1 users are increasingly encouraged to maintain active lifestyles during treatment, making on-the-go nutrition convenience a key product consideration.\u201cUltimately, solutions for GLP-1 analog users need to be simple to understand and enjoyable to consume, while giving consumers the confidence that they align with their weight-management goals,\u201d she explains. \u201cAlthough the industry is already starting to respond to these needs, we would welcome more studies that track what users are actually eating to help inform future innovation.\u201d<\/p>\n

Maintaining muscle mass<\/p>\n

Noting a consequential gap to come out of the GLP-1 trial data, Teresa Pellicer, product manager of Biotechnology at HTBA, flags that up to 40\u201360% of GLP-1-supported weight loss can come from lean muscle mass loss, not fat, if it is not well managed.<\/p>\n

\u201cBut muscle loss was rarely a primary endpoint in the original studies, and the industry is now catching up with a physiological reality that wasn\u2019t fully measured when these drugs were approved.\u201d<\/p>\n

\u201cWhat this points to is a need to shift the conversation from weight loss as a single outcome to the quality of that weight loss. Losing weight matters; losing it while preserving muscle, maintaining energy, and supporting metabolic health is a fundamentally different challenge.\u201d<\/p>\n

Addressing this challenge, Pellicer highlights HTBA\u2019s Leanara \u2014 a dual-effect companion ingredient \u2014 which combines bioflavonoids with highly bioavailable vitamin B12 to fill the nutritional gaps GLP-1 users face \u201cbeyond the number on the scale.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Many GLP-1 clinical trials are not tracking what patients are consuming, pointing to a gap in the weight-loss…\n","protected":false},"author":3,"featured_media":924980,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[373203,12810,3654,210,1060,24295,2236,67,132,68],"class_list":["post-924979","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-companion-products","tag-fat","tag-glp-1","tag-health","tag-medication","tag-metabolic-health","tag-muscles","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116894427353139362","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/924979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=924979"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/924979\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/924980"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=924979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=924979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=924979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}